Immunyfit

Autoimmune and gut-immune disorders are accelerating worldwide, approaching 5% of the global population and disproportionately affecting women, over 80% of cases. Yet millions remain undiagnosed or poorly managed due to low awareness, vague symptoms, complex diagnostics, and limited specialist access. Solving this systemic gap demands a true systems-level approach.

Immunyfit addresses this challenge with biology- and AI-driven precision care, delivering personalized, clinically validated assessments and therapeutic strategies. By making autoimmune care more accurate, proactive, and accessible, particularly for women, the startup directly advances the UN Sustainable Development Goal of promoting good health and well-being.

Immunyfit’s disruptive innovation is a biology-first digital twin that simulates the immune–gut–metabolic network in real time. By integrating systems biology with clinical and multi-omics data, we uncover early, personalized insights beyond the reach of traditional diagnostics. This breakthrough platform transforms autoimmune and gut-immune care and accelerates discovery for women’s health and therapeutic R&D.

Immunyfit’s solution directly advances key United Nations Sustainable Development Goals (SDGs):

• SDG 3: Good Health & Well-being – enabling early, accurate assessment and precision management of autoimmune and gut-immune disorders through biology-first AI and digital twin modeling, improving outcomes for millions—especially women, who account for nearly 80% of all cases.
• SDG 9: Industry, Innovation and Infrastructure – creating a next-generation systems-biology platform that unifies clinical data, multi-omics layers, and computational modeling to deliver scalable, predictive, and globally adaptable healthcare innovation.
• SDG 12: Responsible Consumption & Production – promoting evidence-based, sustainable nutraceutical and microbiome-driven interventions, reducing unnecessary treatments, and enabling more efficient use of healthcare resources.

Immunyfit’s innovation has the potential to transform access to personalized immune-health insights, particularly for underserved communities. By replacing fragmented diagnostics with an integrated, predictive, and clinically validated platform, Immunyfit delivers meaningful impact across patient care, research, and women’s health—driving measurable societal benefit and sustainable progress worldwide.

Immunyfit uses Dassault Systèmes’ 3DEXPERIENCE platform to model and simulate its biology-first immune–gut digital twin, enabling advanced prediction, validation, and accelerated precision-health development.

BIOVIA, ENOVIA, NETVIBES, and MEDIDATA provide integrated capabilities, from computational biology and workflow management to AI-driven analytics and secure clinical data capture, creating a scalable, data-driven ecosystem that accelerates R&D and global growth.

Immunyfit’s journey began within leading Indian innovation ecosystems, including STPI MeitY incubation, the Villgro Foundation, IIM Bangalore NSRCEL, IIM Kozhikode (LIVE), and IIHMR, where its biology-first platform was shaped and strengthened

As Immunyfit advances its digital twin technology, the company continues to build a collaborative network of clinicians, researchers, diagnostics partners, and health-tech innovators—creating a collective ecosystem that accelerates validation, scale, and real-world impact.